219686-43-8

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one is used as a pharmacological agent for its ability to modulate GABA receptors, which is crucial for the development of new drugs targeting neurological and psychiatric disorders. Its multifaceted properties, including sedation, anxiety reduction, muscle relaxation, and anticonvulsant effects, make it a promising candidate for treating conditions such as insomnia, anxiety disorders, muscle spasms, and epilepsy.
Used in Research and Development:
In the field of medicinal chemistry, 7-Bromo-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one serves as a valuable compound for studying the structure-activity relationships of benzodiazepines. Understanding its interactions with GABA receptors can lead to the design of more effective and safer drugs with fewer side effects, ultimately benefiting patients with various neurological and psychiatric conditions.

Upstream product

• 1407832-71-6 methyl 3-((5 -bromo-2-nitrophenyl)amino)propanoate 
• 219686-36-9 5-trifluoroacetyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one 
• 5755-07-7 2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one 
• 219686-38-1 7-bromo-5-trifluoroacetyl-2,3,4,5-tetrahydro-1,5-benzodiazepin-2(1H)-one 
• 1407832-73-8 methyl 3-((2-amino-5-bromophenyl)amino)propanoate 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Relevant academic research and scientific papers

Convenient synthesis of 7-bromo-tetrahydro-1,5-benzodiazepin-2-ones

Treatment of 5-acyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-ones with bromine in the presence of the sulfuric acid afforded products to be brominated exclusively in the aromatic ring at position 7.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains

Inhibition of the bromodomains of the BET family, of which BRD4 is a member, has been shown to decrease myc and interleukin (IL) 6 in vivo, markers that are of therapeutic relevance to cancer and inflammatory disease, respectively. Herein we report substituted benzo[b]isoxazolo[4,5-d]azepines and benzotriazolo[4,3-d][1,4]diazepines as fragment-derived novel inhibitors of the bromodomain of BRD4. Compounds from these series were potent and selective in cells, and subsequent optimization of microsomal stability yielded representatives that demonstrated dose- and time-dependent reduction of plasma IL-6 in mice.

BROMODOMAIN INHIBITORS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.